ArticleDiscover oncology2025
Development and validation of liquid-liquid phase separation-associated prognostic biomarkers in gastric cancer.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveLiquid-liquid phase separation (LLPS) is the membrane-less formation of functional assemblies from specific molecules. It plays a key role in tumor growth by governing gene expression. This study aims to identify LLPS-associated molecular subtypes and prognostic biomarkers in gastric cancer (GC).
methodsLLPS-associated genes, gene expression profiles and clinical data for GC were sourced from public databases. Differential expression analysis, UpSetR package, and Cox regression analyses were employed to pinpoint LLPS-related biomarkers. Consensus clustering was employed to confirm GC molecular subtypes. Mendelian randomization (MR) was applied to uncover causal links between biomarkers and GC risk. The quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) gauged biomarker expression in GC cells (BGC-823, MGC-803, and MKN-45) and normal gastric epithelial cells (GES-1).
resultsTotally 62 LLPS-associated genes were detected. Subsequently, three LLPS-associated subtypes of GC were confirmed, containing subtypes 1, 2 and 3, and patients in subtype 2 had significantly worse overall survival (OS) than subtypes 1 and 3. Furthermore, three LLPS-associated biomarkers (DACT1, PTPN6, and GLE1) were identified for prognostic model construction. Kaplan-Meier (KM) curve suggested that OS was significantly shorter in low-expression of GLE1 and PTPN6 groups than in high-expression groups, respectively, while an opposite trend was observed in DACT1. Notably, MR analysis suggested that DACT1 was associated with the risk of GC. Moreover, qRT-PCR results demonstrated that PTPN6 and GLE1 were significantly higher expressed in GC cell lines compared to GSE-1 cells, whereas the opposite was true for DACT1.
conclusionThis work detected three LLPS-associated prognostic biomarkers (DACT1, PTPN6, and GLE1) for GC. These findings were expected to lead to the development of more precise and effective therapeutic strategies for GC in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.